Article
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
Transplantation - 15 May 1997
Nalesnik M A, Rao A S, Furukawa H, Pham S, Zeevi A, Fung J J, Klein G, Gritsch H A, Elder E, Whiteside T L, Starzl T E
Abstract excerpt
Lymphoreticular malignancies, collectively called posttransplant lymphoproliferative disorders (PTLD), eventually develop in 2-5% of organ transplant recipients. They frequently undergo regression when immunosuppression is reduced or stopped. This feature has been associated with a previous or de novo Epstein-Barr virus (EBV) infection. We herein describe immunotherapy with autologous lymphokine-activated killer...
Topics
- Adult
- Female
- Herpesviridae Infections
- Herpesvirus 4, Human
- Humans
- Immunotherapy, Adoptive
- Interleukin-2
- Killer Cells, Lymphokine-Activated
- Killer Cells, Natural
- Lymphoproliferative Disorders
- Male
- Middle Aged
- Phenotype